Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by KAREN H LU and SHANNON NEVILLE WESTIN.
KAREN H LU
Connection Strength
4.201
SHANNON NEVILLE WESTIN
  1. Translating biological insights into improved management of endometrial cancer. Nat Rev Clin Oncol. 2024 Nov; 21(11):781-800.
    View in: PubMed
    Score: 0.243
  2. Transforming ovarian cancer care by targeting minimal residual disease. Med. 2023 11 10; 4(11):755-760.
    View in: PubMed
    Score: 0.230
  3. Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res. 2021 12 01; 27(23):6354-6365.
    View in: PubMed
    Score: 0.198
  4. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 02; 224(2):191.e1-191.e15.
    View in: PubMed
    Score: 0.184
  5. Rapidly Changing Landscape of Fallopian Tube Carcinoma. J Oncol Pract. 2019 07; 15(7):383-384.
    View in: PubMed
    Score: 0.170
  6. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecol Oncol. 2018 11; 151(2):374-380.
    View in: PubMed
    Score: 0.161
  7. Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. Obstet Gynecol. 2018 01; 131(1):109-116.
    View in: PubMed
    Score: 0.153
  8. A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment. Gynecol Oncol. 2017 08; 146(2):399-404.
    View in: PubMed
    Score: 0.148
  9. A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecol Oncol. 2017 08; 146(2):234-239.
    View in: PubMed
    Score: 0.147
  10. Factors prognostic of survival in advanced-stage uterine serous carcinoma. Gynecol Oncol. 2017 07; 146(1):27-33.
    View in: PubMed
    Score: 0.146
  11. Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study. Gynecol Oncol. 2016 Dec; 143(3):466-471.
    View in: PubMed
    Score: 0.141
  12. Survivors of gynecologic malignancies: impact of treatment on health and well-being. J Cancer Surviv. 2016 Apr; 10(2):261-70.
    View in: PubMed
    Score: 0.130
  13. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. Mol Oncol. 2015 Oct; 9(8):1694-703.
    View in: PubMed
    Score: 0.128
  14. Molecular pathogenesis of endometrial cancers in patients with Lynch syndrome. Cancer. 2013 Aug 15; 119(16):3027-33.
    View in: PubMed
    Score: 0.112
  15. Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations. Gynecol Oncol. 2011 May 01; 121(2):358-63.
    View in: PubMed
    Score: 0.095
  16. Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. Cancer. 2011 Jun 15; 117(12):2659-67.
    View in: PubMed
    Score: 0.094
  17. Molecular clustering of endometrial carcinoma based on estrogen-induced gene expression. Cancer Biol Ther. 2009 Nov; 8(22):2126-35.
    View in: PubMed
    Score: 0.087
  18. Enhanced estrogen-induced proliferation in obese rat endometrium. Am J Obstet Gynecol. 2009 Feb; 200(2):186.e1-8.
    View in: PubMed
    Score: 0.083
  19. Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol. 2008 Dec 20; 26(36):5965-71.
    View in: PubMed
    Score: 0.081
  20. What women with ovarian cancer think and know about genetic testing. Gynecol Oncol. 2008 Oct; 111(1):132-6.
    View in: PubMed
    Score: 0.080
  21. STK15 F31I polymorphism is associated with increased uterine cancer risk: a pilot study. Gynecol Oncol. 2007 Oct; 107(1):71-4.
    View in: PubMed
    Score: 0.074
  22. Long-Term Follow-up of Levonorgestrel Intrauterine Device for Atypical Hyperplasia and Early Endometrial Cancer Reveals Relapse Characterized by Immune Exhaustion. Clin Cancer Res. 2024 Nov 15; 30(22):5073-5082.
    View in: PubMed
    Score: 0.062
  23. The association of the chemotherapy response score and homologous recombination deficiency in patients undergoing interval tumor reductive surgery following neoadjuvant chemotherapy. Int J Gynecol Cancer. 2024 Oct 16.
    View in: PubMed
    Score: 0.061
  24. Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial. Med. 2024 Aug 15; 100494.
    View in: PubMed
    Score: 0.061
  25. Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers. Clin Cancer Res. 2024 Jul 15; 30(14):2986-2995.
    View in: PubMed
    Score: 0.060
  26. Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer. iScience. 2024 May 17; 27(5):109801.
    View in: PubMed
    Score: 0.059
  27. Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis. Med. 2024 Apr 12; 5(4):311-320.e3.
    View in: PubMed
    Score: 0.059
  28. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer. 2024 04 01; 130(7):1061-1071.
    View in: PubMed
    Score: 0.058
  29. Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours. Br J Haematol. 2023 05; 201(3):e25-e29.
    View in: PubMed
    Score: 0.055
  30. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. J Clin Oncol. 2023 03 20; 41(9):1725-1734.
    View in: PubMed
    Score: 0.054
  31. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecol Oncol. 2021 07; 162(1):24-31.
    View in: PubMed
    Score: 0.048
  32. Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Gynecol Oncol. 2021 07; 162(1):65-71.
    View in: PubMed
    Score: 0.048
  33. Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. Gynecol Oncol. 2021 03; 160(3):777-785.
    View in: PubMed
    Score: 0.048
  34. Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol. 2021 04; 161(1):56-62.
    View in: PubMed
    Score: 0.048
  35. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Rep. 2020 04 14; 31(2):107502.
    View in: PubMed
    Score: 0.045
  36. Body mass index and attitudes towards health behaviors among women with endometrial cancer before and after treatment. Int J Gynecol Cancer. 2020 02; 30(2):187-192.
    View in: PubMed
    Score: 0.044
  37. Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study. Clin Cancer Res. 2020 02 01; 26(3):581-587.
    View in: PubMed
    Score: 0.043
  38. Preoperative PET/CT does not accurately detect extrauterine disease in patients with newly diagnosed high-risk endometrial cancer: A prospective study. Cancer. 2019 10 01; 125(19):3347-3353.
    View in: PubMed
    Score: 0.042
  39. Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer. Gynecol Oncol. 2019 07; 154(1):22-28.
    View in: PubMed
    Score: 0.042
  40. Prognostic factors impacting survival in early stage uterine carcinosarcoma. Gynecol Oncol. 2019 01; 152(1):31-37.
    View in: PubMed
    Score: 0.041
  41. Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstet Gynecol. 2018 09; 132(3):545-554.
    View in: PubMed
    Score: 0.040
  42. Three Lymphadenectomy Strategies in Low-Risk Endometrial Carcinoma: A Cost-Effectiveness Analysis. Obstet Gynecol. 2018 07; 132(1):52-58.
    View in: PubMed
    Score: 0.040
  43. Impact of body mass index and operative approach on surgical morbidity and costs in women with endometrial carcinoma and hyperplasia. Gynecol Oncol. 2017 04; 145(1):55-60.
    View in: PubMed
    Score: 0.036
  44. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget. 2016 Jun 07; 7(23):35132-43.
    View in: PubMed
    Score: 0.034
  45. Management of nodal recurrences of endometrial cancer with IMRT. Gynecol Oncol. 2015 Oct; 139(1):40-6.
    View in: PubMed
    Score: 0.032
  46. The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer. Int J Gynecol Cancer. 2014 May; 24(4):713-7.
    View in: PubMed
    Score: 0.030
  47. Utility of MLH1 methylation analysis in the clinical evaluation of Lynch Syndrome in women with endometrial cancer. Curr Pharm Des. 2014; 20(11):1655-63.
    View in: PubMed
    Score: 0.029
  48. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res. 2012 Nov; 22(11):2120-9.
    View in: PubMed
    Score: 0.027
  49. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012 Mar 10; 30(8):777-82.
    View in: PubMed
    Score: 0.025
  50. Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer. 2009 Apr 15; 115(8):1598-604.
    View in: PubMed
    Score: 0.021
  51. Genetic polymorphisms and endometrial cancer risk. Expert Rev Anticancer Ther. 2008 Jul; 8(7):1159-67.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.